Majid Mehtali
Keine laufenden Positionen mehr
Profil
Majid Mehtali served as Chairman at Smol Therapeutics SAS.
Prior to that, he was the Joint Managing Director & Chief Scientific Officer at Vivalis SA from 2010 to 2013.
He also served as Representative Director at Vivalis Toyama Japan KK and as Chief Scientific Officer & Member-Management Board at Valneva SE.
Mehtali received his undergraduate and doctorate degrees from the University of Strasbourg.
Ehemalige bekannte Positionen von Majid Mehtali
| Unternehmen | Position | Ende |
|---|---|---|
| Smol Therapeutics SAS | Vorsitzender | 01.08.2013 |
| VALNEVA | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2013 |
| Vivalis Toyama Japan KK | Direktor/Vorstandsmitglied | 01.08.2013 |
Vivalis SA
 Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | Präsident | 19.07.2010 |
Ausbildung von Majid Mehtali
| University of Strasbourg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VALNEVA | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Vivalis SA
Vivalis SA Pharmaceuticals: OtherHealth Technology Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France. | Health Technology |
| Smol Therapeutics SAS | |
| Vivalis Toyama Japan KK |
